NCT05387044

SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

An Open-label, Phase II Single Arm Trial of SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The treatment modality with immunotherapy has been the first-line standard treatment for advanced NSCLC. But more than 2/3 patients still develop acquired drug resistance within 5 years of immunotherapy, and more than 1/2 patients are oligoprogressive. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. This study aims to evaluate the efficacy and safety of SBRT for oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors.

Conditions

• NSCLC Stage IV

Interventions

Type	Name	Description
RADIATION	SBRT	Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.

Timeline

• Start date: 2022-05-01
• Primary completion: 2023-04-30
• Completion: 2024-04-30
• First posted: 2022-05-24
• Last updated: 2022-05-24

Locations

1 site across 1 country: China